


2025

Catalog

promise
ADVANCED PROTEOMICS

SIL-PROTEINS FOR TARGETED LC-MS QUANTIFICATION



Improve accuracy across your Mass Spectrometry workflows

www.promise-proteomics.com | contact@promise-proteomics.com

SIL-PROTEINS

PROMISE Proteomics is a pioneer and an expert in the development of Mass Spectrometry-based quantification methods and in the bioproduction of Stable Isotope Labelled (SIL) proteins.

Why use our SIL-proteins?

A Stable Isotope Labelled (SIL) form of an analyte protein is widely regarded as the optimal internal standard¹ for absolute quantification of proteins using LC-MS.

SIL-proteins correct bias (due to incomplete digestion, losses, adsorption, proteolysis, etc.) occurring during the preparation and the analytical workflow. With SIL-proteins, the accuracy and reproducibility of your quantification data is improved.


This product is useful for:

- Bioanalysis pharmacokinetics studies (clinical & non-clinical),
- Research & Discovery as well as pre-clinical & clinical Drug Development
- Biomarker's quantification

Characteristics

- **Full length recombinant proteins**
- **Identical to the protein of interest**, same sequence as the native protein
- **High isotopic incorporation, stability and purity**
- **Uniform (U¹⁵N) or specific labelling on Arg, Lys residues (¹³C¹⁵N isotope)**
- **Unlabelled option available**

How to use our solutions?



Unlike the use of SIL-peptides, PROMISE's SIL-proteins are processed along with the target analytes throughout the pre-analytical and LC-MS workflow thus improving robustness and quality of the quantitative data.

1. Faria, M., & Halquist, M. S. (2018). Internal standards for absolute quantification of large molecules (Proteins) from biological matrices by LC-MS/MS. In InTech eBooks. <https://doi.org/10.5772/intechopen.75569>

OFF-THE-SHELF PRODUCTS

SIL-proteins* are available to support your studies and clinical trials.

Your protein of interest is not listed? Please contact our experts for custom bioproduction.

HUMAN PROTEINS	LABELLED		UNLABELLED
	LABELLING	REFERENCES	REFERENCES
Neurodegenerative diseases biomarkers			
Apolipoprotein E3	U ¹⁵ N	AP237306	AP237300
Neurofilament	(Arg,Lys) ¹³ C ¹⁵ N	NF169531	NF169530
Neurofilament	U ¹⁵ N	NF169536	NF169530
Synuclein alpha	(Lys) ¹³ C ¹⁵ N	SY865402	SY865400
Synuclein beta	U ¹⁵ N	SY875286	
Synuclein gamma	U ¹⁵ N	SY925246	
Tau 441	(Arg,Lys) ¹³ C ¹⁵ N	TA928521	TA928520
Tau 352	U ¹⁵ N	TA247576	
GFAP	U ¹⁵ N	GF128226	GF128220
Cardiovascular diseases biomarkers			
Apolipoprotein A1	U ¹⁵ N	AP176846	AP176840
Carboxypeptidase B2	(Arg,Lys) ¹³ C ¹⁵ N	CP618731	
Clusterin protein	(Arg,Lys) ¹³ C ¹⁵ N	CL118321	
NT-proBNP	U ¹⁵ N	BN045556	BN045550
Troponin I	U ¹⁵ N	TN946116	
Metabolic biomarkers			
Albumin	U ¹⁵ N	AL170196	
Cystatin C	U ¹⁵ N	CY725606	CY725600
Vitamin D Binding Protein	(Arg,Lys) ¹³ C ¹⁵ N	DB128581	
Cancer biomarkers			
Alpha Feto Protein	(Arg,Lys) ¹³ C ¹⁵ N	AF099901	
HRAS	(Arg,Lys) ¹³ C ¹⁵ N	RA125711	<i>upon request</i>
KRAS 2A	U ¹⁵ N	RA105856	RA105850
KRAS 2B	(Arg,Lys) ¹³ C ¹⁵ N	RA145561	RA115550
KRAS 2B G12C mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA117051	RA117050
KRAS 2B G12C/C118A mutant			RA119550
KRAS 2B G12C/C51S/C80L/C118S mutant			RA113970
KRAS 2B G12D mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA117061	
KRAS 2B G12R mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA147211	<i>upon request</i>
KRAS 2B G12V mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA147251	<i>upon request</i>
KRAS 2B G13C mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA117381	
KRAS 2B G13D mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA117391	
KRAS 2B Q61H mutant	(Arg,Lys) ¹³ C ¹⁵ N	RA147701	<i>upon request</i>
NRAS	U ¹⁵ N	RA985806	RA985800
PD1	(Arg,Lys) ¹³ C ¹⁵ N	<i>upon request</i>	
PDL1	(Arg,Lys) ¹³ C ¹⁵ N	<i>upon request</i>	
Peptidic hormones			
Choriogonadotropin	(Arg,Lys) ¹³ C ¹⁵ N	CG115931	
Erythropoietin	(Arg,Lys) ¹³ C ¹⁵ N	EP085791	
Growth hormone 22	U ¹⁵ N	GH596296	GH596290
Growth hormone 22	(Arg,Lys) ¹³ C ¹⁵ N	GH596291	GH596290
Sepsis biomarker			
Procalcitonin	U ¹⁵ N	PC675516	PC675620



*for Research Use Only

✉ contact@promise-proteomics.com

REFERENCES

Peer reviewed publications using our SIL-proteins

- **Laboratoire National de Métrologie et d'Essais (LNE)**

Giangrande, C. *et al.* (2023). Development of a candidate reference measurement procedure by ID-LC-MS/MS for total TAU protein measurement in cerebrospinal fluid (CSF). *Clinical Chemistry and Laboratory Medicine*, 61(7), 1235-1244. <https://doi.org/10.1515/cclm-2022-1250>

- **Janssen**

Bijttebier, S. *et al.* (2023). IP-LC-MSMS enables identification of three TAU O-GLCNAcylation sites as O-GLCNAcase inhibition pharmacodynamic readout in transgenic mice overexpressing human TAU. *Journal of Proteome Research*, 22(4), 1309-1321. <https://doi.org/10.1021/acs.jproteome.2c00822>

- **Washington University School of Medicine**

Lawler, P. E., *et al.* (2023). Apolipoprotein E o-glycosylation is associated with amyloid plaques and APOE genotype. *Analytical Biochemistry*, 672, 115156. <https://doi.org/10.1016/j.ab.2023.115156>

- **INSERM**

Pons, M. *et al.* (2023). Absolute quantification of synuclein proteoforms in plasma in patients with synucleinopathies by LC-MRM mass spectrometry. *medRxiv* (Cold Spring Harbor Laboratory). <https://doi.org/10.1101/2023.07.17.23292753>

- **Merck**

Johns, D. G. *et al.* (2023). Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. *Circulation*, 148(2), 144-158. <https://doi.org/10.1161/circulationaha.122.063372>

- **University Medical Center Utrecht**

Smeijsters, E. H. E. *et al.* (2023). Optimization of a quantitative Anti-Drug Antibodies against Infliximab assay with the liquid Chromatography-Tandem Mass Spectrometry : A Method Validation Study and Future Perspectives. *Pharmaceutics*, 15(5), 1477. <https://doi.org/10.3390/pharmaceutics15051477>

- **TUBITAK National Metrology Institute (TUBITAK UME)**

Ascioglu, M., Öztug, M., & Karagüler, N. G. (2023). Development of an ID-LC-MS/MS method using targeted proteomics for quantifying cardiac troponin I in human serum. *Clinical Proteomics*, 20(1). <https://doi.org/10.1186/s12014-023-09430-z>

- **Johns Hopkins University**

Smith, J. W. *et al.* (2023). Global discovery and Temporal changes of human albumin modifications by Pan-Protein adductomics : Initial application to air pollution exposure. *Journal of the American Society for Mass Spectrometry*, 34(4), 595-607. <https://doi.org/10.1021/jasms.2c00314>

- **Genentech**

Meng, M. *et al.* (2022). Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. *Analytical Chemistry*, 94(37), 12927-12933. <https://doi.org/10.1021/acs.analchem.2c03146>

- **Washington University School of Medicine**

Budelier, M. M. *et al.* (2022). A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. *Brain Communications*, 4(2). <https://doi.org/10.1093/braincomms/fcac045>

- **AstraZeneca**

Kantae, V. *et al.* (2022). Accelerating the Validation of Endogenous On-Target Engagement and In-cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery. *bioRxiv*. <https://doi.org/10.1101/2022.02.17.480880>

REFERENCES

Peer reviewed publications using our SIL-proteins

- **Genentech**

Meng, M. *et al.* (2022). Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. *Analytical Chemistry*, 94(37), 12927-12933. <https://doi.org/10.1021/acs.analchem.2c03146>

- **Washington University School of Medicine**

Budelier, M. M. *et al.* (2022). A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer's disease. *Brain Communications*, 4(2). <https://doi.org/10.1093/braincomms/fcac045>

- **AstraZeneca**

Kantae, V. *et al.* (2022). Accelerating the Validation of Endogenous On-Target Engagement and In-cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery. *bioRxiv*. <https://doi.org/10.1101/2022.02.17.480880>

- **Janssen**

Bijttebier, S. *et al.* (2021). Development of immunoprecipitation – two-dimensional liquid chromatography – mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients. <https://doi.org/10.1016/j.chroma.2021.462299>

- **National Institute of Standards and Technology**

Schneck, N. A., *et al.* (2018). Quantification of cardiac troponin I in human plasma by immunoaffinity enrichment and targeted mass spectrometry. *Analytical and Bioanalytical Chemistry*, 410(11), 2805-2813. <https://doi.org/10.1007/s00216-018-0960-7>

- **Wellspring Biosciences**

Hansen, R. *et al.* (2018). An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors. *Scientific Reports*, 8(1). <https://doi.org/10.1038/s41598-018-32683-w>

- **Wellspring Biosciences**

Janes, M. R. *et al.* (2018). Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell*, 172(3), 578–589.e17. <https://doi.org/10.1016/j.cell.2018.01.006>

- **University Hospital Grenoble-Alpes**

Maes, P. *et al.* (2017). Introducing plasma/serum glycodepletion for the targeted proteomics analysis of cytolysis biomarkers. *Talanta*, 170, 473-480. <https://doi.org/10.1016/j.talanta.2017.04.042>

- **University Hospital Grenoble-Alpes**

Gilquin, B. *et al.* (2017). Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics. *Talanta*, 164, 77-84. <https://doi.org/10.1016/j.talanta.2016.11.023>

- **Merck**

McAvoy, T. *et al.* (2014). Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry. *Clinical Chemistry*, 60(4), 683-689. <https://doi.org/10.1373/clinchem.2013.216515>

- **INSERM**

Lebert, D. *et al.* (2011). Production and Use of Stable Isotope-Labeled Proteins for Absolute Quantitative Proteomics. *Methods in Molecular Biology*, 93-115. https://doi.org/10.1007/978-1-61779-148-2_7

PROMISE Proteomics S.A.S.

7, parvis Louis Néel • BHT 52 A • CS 20050 - 38040 Grenoble Cedex 9 • FRANCE

Phone: +33 438 023 650 | RCS Grenoble B 433 546 504